A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study in rheumatoid arthritis participants inadequately responding to biologics.

Timeline

Start

2016-11-26

Primary completion

2018-05-16

Completion

2019-11-25

Outcome

Missed primary endpoint

registry p = 0.621; Difference from Placebo -4.7 (95% CI -25.85 to 16.46) NCT02960490 ↗

Drugs

Indications